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ABSTRACT
Background: Irisin is an exercise induced myokine that is shown to promote 
browning of adipose tissue and hence, increase energy expenditure. Furthermore, our 
unpublished results indicate that Irisin improves myogenic differentiation and induces 
skeletal muscle hypertrophy. Since exercise induced skeletal muscle hypertrophy 
improves muscle strength, we wanted to investigate if ectopic injection of Irisin 
peptide improves skeletal muscle function in a mouse model of muscular dystrophy. 
This utility of Irisin peptide is yet to be studied in animal models.
Methods: In order to test this hypothesis, we expressed and purified recombinant 
murine Irisin peptide from E. coli. Three- to six-week-old male mdx mice were injected 
IP with either vehicle (dialysis buffer) or Irisin recombinant peptide for two or four 
weeks, three times-a-week.
Results: Irisin injection increased muscle weights and enhanced grip strength in 
mdx mice. Improved muscle strength can be attributed to the significant hypertrophy 
observed in the Irisin injected mdx mice. Moreover, Irisin treatment resulted in 
reduced accumulation of fibrotic tissue and myofiber necrosis in mdx mice. In addition, 
Irisin improved sarcolemmal stability, which is severely compromised in mdx mice.
Conclusion: Irisin injection induced skeletal muscle hypertrophy, improved 
muscle strength and reduced necrosis and fibrotic tissue in a murine dystrophy 
model. These results demonstrate the potential therapeutic value of Irisin in muscular 
dystrophy.
INTRODUCTION
Duchenne Muscular Dystrophy (DMD) is a common 
form of muscle wasting seen in young boys and is caused 
by mutations in the dystrophin gene [1]. Mutation of the 
dystrophin gene results in the production of a defective 
dystrophin protein leading to membrane fragility 
and muscle necrosis [2]. The functionality of muscle 
deteriorates in muscular dystrophy patients over time due 
to repeated cycles of skeletal muscle degeneration and 
regeneration, leading to muscle weakness [2]. Moreover, 
myofibers are progressively replaced by collagen, which 
promotes fibrosis and weakening of muscle. [3]. In 
the late stages of muscular dystrophy, patients become 
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wheelchair bound since activities like walking become 
challenging and patients often die prematurely due to heart 
and respiratory failure [4]. Currently there are no known 
therapies to overcome DMD or any form of muscular 
dystrophy.
The naturally occurring mdx mouse model of 
DMD [5] is one of the most widely used models to study 
the pathophysiology of DMD. During the early stage 
of the disease, at 3 weeks of age, mdx mice undergo 
a sudden onset of muscular necrosis [6]. This acute 
onset of muscular dystrophy provides a good platform 
to investigate potential therapeutic molecules, which 
could alleviate this condition by reducing necrosis and 
improving muscle strength. Mdx muscle growth is slower 
than that of the wild type controls and hence, they have 
smaller fibers, myonuclear domains and less myonuclei 
[7]. Three week old mdx mice undergo severe muscle fiber 
destruction and subsequent complete regeneration, which 
leads to muscle fiber necrosis [8]. After 8 weeks of age, 
the extent of muscle fiber damage decreases and stabilizes 
despite repeated rounds of fiber necrosis and regeneration 
[8]. By 12 to 14 weeks of age, mdx mice attain the 
maximum size of muscle fibers, which are hyper-nucleated 
with more centrally placed nuclei [7].
Irisin is a newly discovered myokine that is induced 
in response to exercise [9]. The 112 amino acid protein 
Irisin, is formed through processing of the precursor 
protein FNDC5. Upon cleavage, mature Irisin protein is 
secreted into circulation and has been shown to induce 
the expression of genes that promote browning of beige 
adipose tissue, such as Ucp-1, Cidea, Cpt1b and Dio2 
[9]. The effect of Irisin in mouse models is distinct and 
well established. However, the role of Irisin in humans 
remains controversial. Although Boström et al., (2012) 
demonstrated that exercise resulted in increased serum 
Irisin levels in humans, more recent work from Raschke 
et al., (2013) revealed the absence of a canonical 
translational start codon in human Irisin, which indicated 
the production of a non-functional Irisin protein in humans 
[10]. Moreover, a separate study of commercially available 
antibodies by Albrecht et al., (2015) provided evidence 
to suggest that all commercial antibodies, available at 
the time, were unable to detect circulating Irisin protein 
in humans [11]. However, recent work by Jedrychowski 
et al, (2015) revealed that although human Irisin protein 
contains a non-canonical start codon, the full length 
Irisin precursor protein FNDC5 is translated, indicating 
complex regulation of translation. FNDC5 protein is 
present in human skeletal muscle and is cleaved to give 
rise to detectable levels of Irisin in circulation. In fact, the 
level of Irisin in circulation is more abundant than other 
commonly known circulating proteins, such as Insulin and 
Interleukin 6 (IL6). In addition, the authors showed that 
Irisin levels are elevated in response to exercise in humans 
and is indeed an exercise induced myokine as previously 
reported by Boström et al., (2012) [12].
In humans, circulating Irisin levels are positively 
correlated with biceps circumference and expression 
of IGF-1 [13]. This suggests that elevated levels of 
Irisin may lead to increased skeletal muscle mass. In 
agreement with this, elevated Irisin levels have been 
observed in myostatin-null mice, which display a 
dramatic double muscled phenotype [14]. Recently, 
it was further shown that Irisin is able to stimulate 
muscle growth-related genes in humans [15]. In human 
myocytes, Irisin secretion has been shown to increase 
during myogenic differentiation and Irisin treatment 
resulted in increased p-Erk expression, which is a key 
protein involved in the protein synthesis pathway [15]. 
Consistent with these results, recent unpublished data 
from our laboratory demonstrate that Irisin improves 
myogenic differentiation of C2C12 myoblasts and 
induces significant muscular hypertrophy when injected 
into wild type C57BL6/J mice. Taken together these 
studies reveal that increased levels of Irisin could 
promote skeletal muscle growth.
To study the potential therapeutic role of Irisin in 
increasing skeletal muscle growth, we investigated the 
effect of recombinant Irisin protein on skeletal muscle 
mass, quality and function in the mdx mouse model of 
DMD. Our results strongly suggest that Irisin is able to 
improve skeletal muscle mass and strength of dystrophic 
mdx mice, reduce fibrotic tissue accumulation as well as 
reduce necrosis of muscle fibers. Moreover, Irisin is able 
to protect dystrophic muscle from sarcolemmal instability, 
which could be indicative of enhanced muscle function in 
mdx mice. These data underscore the therapeutic potential 
of Irisin in improving skeletal muscle mass and protecting 
against dystrophic skeletal muscle loss.
RESULTS
Irisin injection promotes muscular hypertrophy 
in young mdx mice
SDS-PAGE analysis showed that the Histidine-
tagged Irisin protein purified from E.coli is a 
homogenous protein (Figure 1a). Young (3-week-old) 
mdx mice were injected with either dialysis buffer 
(DB) or Irisin. Irisin injected mice showed a significant 
increase in the percentage change in body weight 
just after one week of Irisin injection (Injection 4). 
The significant increase in body weight was further 
maintained throughout the trial (Figure 1b). No distinct 
difference in food intake was noted between DB and 
Irisin injected mice (Figure 1c). Analysis of hind limb 
muscle tissue weights revealed an increase in the weights 
of all muscles analyzed, although with the exception of 
M. soleus (Sol) muscle, the increase was not statistically 
significant (Figure 1d and 1e). Histological analysis 
on transverse sections of the M. tibialis anterior 
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(TA) muscle revealed hypertrophy of muscle fibers 
(Figure 1f); with an increased proportion of fibers with 
larger cross sectional area (>2500μm2) and a reduced 
proportion of fibers with smaller cross sectional area 
(<2500μm2) (Figure 1g and 1h).
Irisin injection protects young mdx mice from 
dystrophic myofiber damage
Skeletal muscle in mdx mice undergoes constant 
cycles of degeneration and regeneration. One of the 
hallmark features of newly formed (regenerated) 
muscle fibers is centrally placed nuclei. As such, we 
next quantified the number of myofibers with centrally 
placed nuclei in DB and Irisin injected mice, to assess if 
Irisin treatment improves postnatal myogenesis in mdx 
mice. Our analysis revealed a ~20% increase (albeit not 
statistically significant) in the percentage of myofibers 
with centrally placed nuclei in mice injected with 
Irisin, when compared to DB controls (Figure 2a). The 
percentage of necrotic muscle fibers was also quantified 
between DB and Irisin injected mdx mice, as assessed 
through the presence of infiltrating mono-nucleated 
cells, myofibers with fragmented sarcoplasm and 
hyper-contracted myofibers. Subsequent quantification 
revealed a 9% reduction in necrotic myofibers in 
mdx mice injected with Irisin, when compared to DB 
treated controls (Figure 2b); however, the reduction 
was not found to be statistically significant (Figure 
2b). We further injected Evans Blue Dye (EBD) 
into DB and Irisin injected mdx mice (Figure 2c) to 
assess myofiber permeability. Red fluorescent EBD 
positive (Figure 2c) myofibers were assessed and the 
percentage of fluorescent muscle fibers was quantified 
through microscopy. Results revealed a significant 75% 
reduction in red fluorescent fibers in the TA muscles of 
mdx mice injected with Irisin, when compared to DB 
injected controls (Figure 2d). The level of Utrophin, 
a homologue of dystrophin, which is expressed in 
dystrophic muscle, was assessed in M. Gastrocnemius 
(Gas) muscle following two weeks of Irisin injection. 
Utrophin expression was normalized to the housekeeping 
protein, Vinculin. Results revealed a slight reduction, 
in the levels of Utrophin in mdx mice injected with 
Irisin, when compared to DB injected controls, albeit 
not statistically significant (Figure 2e and 2f). We next 
measured the creatine kinase (CK) activity in the serum 
of the mdx mice, which is used as a marker to identify 
the extent of muscular dystrophy, since increased CK 
level is associated with muscular dystrophy. However, 
we did not observe a distinct difference in CK activity in 
serum collected from mdx mice injected with either DB 
or Irisin (Figure 2g). Taken together, these data reveal 
that Irisin treatment is able to, at least in part, alleviate 
the dystrophic phenotype in young mdx mice.
Irisin promotes skeletal muscle hypertrophy and 
protects against fibrosis, myofiber necrosis and 
sarcolemmal instability in adult mdx mice
In order to determine the therapeutic potential of 
Irisin in alleviating the dystrophic phenotype observed in 
adult mdx mice, 6-week-old (adult) mdx mice were injected 
with either DB or Irisin three times-a-week for two weeks. 
No significant difference in body weight (Figure 3a) or 
food intake (Figure 3b) was noted between DB and Irisin 
injected adult mdx mice. However, consistent with results 
noted upon injection of young mdx mice with Irisin, an 
increase in weights of TA, M. extensor digitorum longus 
(EDL), Sol, M. quadriceps (Quad) and M. biceps femoris 
(BF) muscles was seen in adult mice injected with 
Irisin, although the increase in muscle weights was not 
statistically significant (Figure 3c and 3d). Histological 
analysis on transverse sections of the TA muscle revealed 
hypertrophy of muscle fibers (Figure 3e). Specifically, an 
increased proportion of fibers with larger cross sectional 
area (>2000μm2) and a reduced proportion of fibers with 
smaller cross sectional area (<2000μm2) was observed 
in Irisin injected adult mdx mice, when compared to DB 
injected controls (Figure 3f and 3g). It is noteworthy to 
mention that TA muscles from adult mdx mice injected 
with Irisin had a large number of myofibers with very 
large cross sectional area (>4000μm2), when compared 
to DB injected controls (Figure 3f and 3g). These data 
strongly suggest that Irisin promotes significant skeletal 
muscle hypertrophy in adult mdx mice. It is also important 
to mention that two weeks of Irisin treatment resulted in 
a more profound hypertrophy of skeletal muscle in adult 
mdx mice, when compared to young mdx mice (Compare 
Figure 1g and 1h with Figure 3f and 3g).
To further understand the beneficial effects of Irisin 
on mdx muscle, we next analyzed the difference in the 
proportion of regenerating muscle fibers, as represented 
by the number of centrally placed nuclei, between adult 
mdx mice injected with either DB or Irisin. It is interesting 
to note that despite the increase in myofiber cross sectional 
area noted in the TA muscle from Irisin injected mdx mice, 
the proportion of myofibers with centrally placed nuclei 
was not significantly different (Figure 4a), with ~41% and 
~46% of myofibers containing centrally formed nuclei 
in DB and Irisin injected mdx mice, respectively. To 
confirm that the increase in muscle weights was not due 
to increased accumulation of fibrotic tissue and collagen, 
we performed Sirius Red (collagen) and Fast green (non-
collagenous proteins) staining of skeletal muscle sections 
from TA muscle of DB and Irisin injected mdx mice 
(Figure 4b). Subsequent quantification of the fibrotic area 
(red) revealed a significant ~4-fold reduction in fibrosis in 
TA muscle from Irisin injected mdx mice, when compared 
to DB injected mice (Figure 4c), suggesting that Irisin 
treatment protected dystrophic muscle fibers against 
fibrotic tissue accumulation.
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Figure 1: Irisin injection increases skeletal muscle mass and promotes hypertrophy in young mdx mice. (a) Representative 
image of Coomassie stained protein gel displaying purified recombinant His-tagged Irisin protein. A single band at ~15kDa was detected for 
recombinant Irisin protein. Lane 1 shows the SeeBlue Plus 2 Pre-Stained ladder. Lanes 2, 3 and 4 show 1μg, 2μg and 3μg of the purified His- 
tagged Irisin protein, respectively. (b) Graph showing percentage change in body weight of young (3-week-old) male mdx mice injected 
three times-a-week with either DB or Irisin (2.5μg/gram body weight) for two weeks. Body weights were measured prior to each injection. 
(c) Graph showing average daily food intake per mouse. Food intake was measured prior to each injection over the two-week trial. (d) 
Graph showing the average weight of TA, EDL and Sol skeletal muscle tissues, normalized to tibia length (g/cm), from young mdx mice 
injected with either DB or Irisin for two weeks. (e) Graph showing the average weight of Quad and Gas skeletal muscle tissues, normalized 
to tibia length (g/cm), from young mdx mice injected with either DB or Irisin for two weeks (n=5 mice per group for all experiments above). 
(f) Representative images of Haematoxylin and Eosin (H&E) stained TA muscle cross sections obtained from young mdx mice injected 
with either DB or Irisin for two weeks. Images were captured using a 20x objective. Scale bar represents 100μm. (g-h) Graphs showing 
the distribution of TA myofiber CSA from young mdx mice injected with either DB or Irisin for two weeks. (n=3 mice per group). Error 
bars represent mean ± SEM. For all relevant figures, the appropriate statistical analysis was performed and significance is indicated with 
* (P<0.05).
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Figure 2: Irisin injection protects young mdx mice from dystrophic-associated skeletal muscle degeneration. (a) Graph 
showing the percentage of myofibers with centrally placed nuclei in TA muscle from young mdx mice injected with either DB or Irisin 
for two weeks. (b) Graph showing the percentage of necrotic fiber area in TA muscle from young mdx mice injected with either DB or 
Irisin for two weeks. (c) Representative images of Evans blue dye (EBD) stained TA muscle cross sections obtained from young mdx mice 
injected with either DB or Irisin for two weeks. White arrows indicate a selection of representative EBD positive myofibers. EBD positive 
myofibers were visualized using fluorescent microscopy under a 20x objective. Scale bar represents 100μm. Linear brightness and contrast 
of images was adjusted to visualize EBD positive myofibers without altering the interpretation of results in any way. (d) Graph showing 
the percentage of EBD incorporation in TA muscle of young mdx mice injected with either DB or Irisin for two weeks. (e) Western Blot 
analysis of Utrophin protein levels in Gas muscle isolated from young mdx mice injected with either DB or Irisin for two weeks. The 
levels of Vinculin were assessed as a loading control. (f) Graph showing densitometric analysis of Utrophin protein levels in arbitrary units 
(A.U), normalized to Vinculin (n=3 mice for all figures above). (g) Graph representing creatine kinase activity in serum of young mdx 
mice injected with DB or Irisin (n=5 mice for both groups). Error bars represent ± SEM. For all relevant figures, the appropriate statistical 
analysis was performed and significance is indicated with * (P<0.05).
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Figure 3: Irisin injection enhances muscle weights and promotes skeletal muscle hypertrophy in adult mdx mice. (a) 
Graph showing average body weights of adult (6-week-old) male mdx mice injected three times-a-week with either DB or Irisin (2.5μg/
gram body weight) for two weeks. Body weights were measured prior to each injection. (b) Graph showing average daily food intake per 
mouse. Food intake was measured prior to each injection over the two-week trial. (c) Graph showing the average weight of TA, EDL and 
Sol skeletal muscle tissues, normalized to tibia length (g/cm), from adult mdx mice injected with either DB or Irisin for two weeks. (d) 
Graph showing the average weight of Gas, Quad and BF skeletal muscle tissue, normalized to tibia length (g/cm), from adult mdx mice 
injected with either DB or Irisin for two weeks (n=6 mice per group for all experiments above). (e) Representative images of Haematoxylin 
and Eosin (H&E) stained TA muscle cross sections obtained from adult mdx mice injected with either DB or Irisin for two weeks. Images 
were captured using a 20x objective. Scale bar represents 100μm. (f-g) Graphs showing the distribution of TA myofiber CSA from adult 
mdx mice injected with either DB or Irisin for two weeks (n=4 mice per group for all experiments above). Error bars represent mean ± 
SEM. For all relevant figures, the appropriate statistical analysis was performed and significance is indicated with * (P<0.05), ** (P<0.01) 
and *** (P<0.001).
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Figure 4: Irisin protects adult mdx mice from fibrotic tissue accumulation and muscle fiber degeneration. (a) Graph 
showing the percentage of myofibers with centrally placed nuclei in TA muscle from adult mdx mice injected with either 
DB or Irisin for two weeks (n=4 mice for both groups). (b) Representative images of Sirius red and Fast green stained TA 
muscle cross sections obtained from adult mdx mice injected with either DB or Irisin for two weeks. The green stain indicates 
non-collagenous proteins, while the red stain indicates collagen. Black arrows indicate a selection of representative fibrotic 
areas. Images were captured using a 40x objective. Scale bar represents 100μm. (c) Graph showing fibrotic area (red stain), 
expressed as a percentage of total muscle section area, in TA muscle from adult mdx mice injected with either DB or Irisin for 
two weeks, as assessed through Sirius red and Fast green staining. (d) Graph showing the percentage of necrotic fiber area 
in TA muscle from adult mdx mice injected with either DB or Irisin for two weeks (n=3 mice per group for all experiments 
above). (e) Representative images of IgM antibody stained TA muscle sections obtained from adult mdx mice injected with 
either DB or Irisin for two weeks. White arrows indicate a selection of representative IgM positive myofibers. Images were 
captured using a 20x objective. Scale bar represents 100μm. Linear brightness and contrast of images was adjusted to visualize 
IgM positive myofibers without altering the interpretation of results in any way. (f) Graph showing IgM stained area, expressed 
as a percentage of total muscle section area, in TA muscle sections from adult mdx mice injected with either DB or Irisin for 
two weeks. (g) Western Blot analysis of Utrophin protein levels in Gas muscle isolated from adult mdx mice injected with 
either DB or Irisin for two weeks. The levels of Vinculin were assessed as a loading control. (h) Graph showing densitometric 
analysis of Utrophin protein levels in arbitrary units (A.U), normalized to Vinculin (n=4 mice per group for all experiments 
above). Error bars represent mean ± SEM. For all relevant figures, the appropriate statistical analysis was performed and 
significance is indicated with * (P<0.05) and ** (P<0.01).
Oncotarget98560www.impactjournals.com/oncotarget
We next assessed the necrotic muscle fiber area in 
muscles isolated from adult mdx mice injected with either 
DB or Irisin. Adult mdx mice injected for two weeks with 
Irisin displayed a dramatic 43% reduction in necrotic 
muscle fibers, when compared to respective DB controls 
(Figure 4d). Taken together these data reveal a role for 
Irisin in protecting against myofiber necrosis in adult mdx 
mice.
Myofibers in mdx mice have reduced sarcolemmal 
stability, which allows proteins that are usually found 
only in circulation to enter and accumulate in the 
degenerating muscle fibers. To understand the role of Irisin 
in protecting sarcolemmal integrity of muscle from mdx 
mice, we investigated the accumulation of IgM protein in 
myofibers, which is typically restricted to circulation in 
healthy mice. Subsequent analysis revealed that a large 
proportion of the myofibers from mdx mice injected with 
DB stained positively for IgM (Figure 4e). However, Irisin 
injection resulted in a significant 58% reduction in IgM 
accumulation in myofibers from mdx mice (Figure 4f). 
These data suggest that Irisin improves the sarcolemmal 
stability of dystrophic myofibers. Lastly, we investigated 
the levels of Utrophin in adult mdx mice injected with 
either DB or Irisin. Similar to the results obtained 
above (Figure 2e and 2f), we observed slight reduction 
in Utrophin levels in adult mdx Gas muscle (Figure 4g 
and 4h). However, the reduction was not statistically 
significant.
Prolonged Irisin treatment increases muscle 
weights and enhances grip strength of mdx mice
As described above, short-term (2 weeks) injection 
of Irisin into mdx mice tended to increase skeletal muscle 
weights, although the increase noted in muscle weights 
was not statistically significant. Given this, we next wanted 
to investigate whether or not increasing the duration of 
Irisin treatment of mdx mice could improve skeletal 
muscle weight and function. To study this, 4-week-old mdx 
mice were injected with either DB or Irisin, three times-
a-week for 4 weeks. No significant difference in body 
weight (Figure 5a) or food intake (Figure 5b) was noted 
between mdx mice injected with either DB or Irisin for 4 
weeks. However, analysis of individual hind limb skeletal 
muscle weights revealed a significant increase in TA, 
Sol and Gas muscle weights in Irisin injected mdx mice, 
when compared to DB injected controls (Figure 5c and 
5d). The weights of EDL, Quad and BF skeletal muscles 
also showed an increase. However, this change was not 
statistically significant (Figure 5c and 5d). Importantly, 4 
weeks of Irisin injection further resulted in a significant 
increase (~2-fold) in the forelimb grip strength of mdx 
mice (Figure 5e). These data indicate that prolonging the 
duration of Irisin treatment could improve both skeletal 
muscle mass and muscle strength of mdx mice.
DISCUSSION
Irisin is a novel exercise-induced myokine and to 
date the role of Irisin on adipose tissue [16] and in type 
II diabetes [17, 18] has been researched extensively. 
Exercise is known to confer significant beneficial 
effects on skeletal muscle, especially through enhancing 
muscle strength through hypertrophy [19–22]. Since 
Irisin is a myokine and is found in significantly higher 
concentrations post-exercise [12], we reasoned that 
Irisin might function in an autocrine/paracrine manner to 
impart beneficial effects of exercise on skeletal muscle. 
Here we show that exogenous Irisin injection resulted 
in muscle hypertrophy and enhanced grip strength in 
dystrophic mice. Irisin treatment also reduced fibrosis 
and necrosis in dystrophic muscle fibers. Moreover, 
Irisin improved sarcolemmal integrity in the absence 
of dystrophin in mdx mice. Taken together, these data 
exemplify the therapeutic benefit of Irisin in improving 
muscle mass, muscle healing and muscle function in a 
dystrophic mouse model.
To assess the effect of Irisin on dystrophic muscle 
loss we have undertaken studies in both young and adult 
mdx mice. We have utilized mdx mice in the current 
study, as this model has been extensively used to study 
the pathophysiology of DMD [23]. Acute onset of the 
dystrophic phenotype, which includes myofiber necrosis 
and elevated creatine kinase levels, occurs in mdx mice at 
3 weeks of age, with a gradual decrease in the intensity of 
the phenotype observed from 8 weeks of age onwards [8]. 
A low level chronic dystrophic pathology is maintained in 
mdx mice throughout their life, with a further reduction in 
severity noted after one year [24].
Initially, we assessed the effect of exogenous Irisin 
treatment on young (3-week-old) mdx mice undergoing 
acute dystrophic muscle loss. It is important to mention 
that we did not observe any adverse effects on the mice in 
response to Irisin injection. Parameters such as movement, 
behavior, or food consumption did not show significant 
differences after Irisin injection. The Irisin injected 
mice did not show inflammation, organ toxicity or fluid 
retention upon gross pathological examination. This 
indicated that the Irisin protein used for the experiments 
was safe for injection into the mice. Interestingly, while 
no apparent difference in food intake was noted between 
DB and Irisin injected mice (Figure 1c), a significant 
increase in percentage body weight change was observed 
in Irisin injected mdx mice (Figure 1b). We propose that 
the increased body weight was due in part, to increased 
muscle mass. Consistent with this, increased muscle 
weights (Figure 1d and 1e) (although not statistically 
significant) and mild myofiber hypertrophy was noted in 
three-week-old Irisin injected mdx mice (Figure 1f-1h).
Further results suggest that Irisin injection may have 
benefits in alleviating the dystrophic phenotype observed 
in skeletal muscle of mdx mice. A trend towards reduced 
myofiber necrosis was noted in young mdx mice following 
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two weeks of Irisin injection, albeit not statistically 
significant (Figure 2b). During muscular dystrophy, 
the absence of dystrophin protein severely diminishes 
sarcolemmal stability and hence, proteins like albumin, 
which are otherwise restricted to circulation, are able to 
cross the sarcolemma and accumulate in myofibers [25]. 
Evans blue dye binds to serum albumin with high affinity 
and hence, Evans blue dye accumulation in skeletal 
muscle can be used as an accurate indicator of muscle 
damage [26] [27]. Importantly, a significant reduction in 
Evans blue dye accumulation was noted in myofibers of 
mdx mice injected with Irisin, which further suggests that 
Irisin may be able to protect myofibers from sarcolemmal 
damage during dystrophy (Figure 2c and 2d).
CK is an enzyme predominantly present in skeletal 
muscle, heart and the brain [28]. During muscular 
dystrophy, CK leaks out from skeletal muscle resulting in 
a spike in the levels of CK in circulation [23]. Despite 
Figure 5: Prolonged Irisin injection increases skeletal muscle mass and enhances muscle function in mdx mice. (a) 
Graph showing average body weight of 4-week-old male mdx mice injected three times-a-week with either DB or Irisin (2.5μg/gram body 
weight) for four weeks. Body weights were measured prior to each injection. (b) Graph showing average daily food intake per mouse. 
Food intake was measured prior to each injection over the four-week trial. (c) Graph showing the average weight of TA, EDL and Sol 
skeletal muscle tissues, normalized to tibia length (g/cm), from 4-week-old mdx mice injected with either DB or Irisin for four weeks. (d) 
Graph showing the average weight of Gas, Quad and BF skeletal muscle tissues, normalized to tibia length (g/cm), from 4-week-old mdx 
mice injected with either DB or Irisin for four weeks. (e) Graph showing the forelimb grip strength (N) of 4-week-old mdx mice injected 
with either DB or Irisin for four weeks. Grip strength was assessed prior to termination of the mice. (n=3 mice for the DB injected control 
group and n=4 mice for the Irisin injected group for all experiments above). Error bars represent mean ± SEM. For all relevant figures, the 
appropriate statistical analysis was performed and significance was indicated with * (P<0.05).
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the reduced myofiber necrosis and improved sarcolemmal 
integrity noted in mdx mice muscle following Irisin 
injection, no significant reduction in the levels of CK 
was observed in serum collected from Irisin injected mdx 
mice, when compared to DB injected controls (Figure 2g). 
We propose that the disparity between reduced necrosis/
improved sarcolemmal integrity and the unaltered CK 
levels noted in serum may be due to the increased muscle 
mass observed in Irisin injected mdx mice. In other words, 
the increased skeletal muscle mass induced in response to 
Irisin injection may have masked the expected reduction 
in systemic CK activity. In agreement with this, a recent 
publication by Relizani et al., (2014) reported that 
blockade of Myostatin signaling in mdx mice, using a 
soluble form of the Activin Type II B receptor (sActRIIB), 
resulted in increased myofiber size in Soleus muscle 
without altering the overall levels of CK in serum [29]. 
Therefore, it is plausible that serum CK levels may not 
accurately reflect the extent of muscle damage present in 
Irisin injected mdx mice. However, it is quite possible that 
the protective role of Irisin was not sufficient to reduce 
the levels of serum CK in young mdx mice and perhaps 
prolonged Irisin treatment may have been required.
Similar to the changes in muscle mass noted in 
young Irisin injected mdx mice, injection of Irisin into 
adult mdx mice resulted in increased muscle weights, 
although the increase was not statistically significant 
(Figure 3c and 3d). However, with just two weeks of 
Irisin injection, a more pronounced hypertrophy of skeletal 
muscle was noted in Irisin injected adult mdx mice (Figure 
3e-3g), when compared to young mdx mice (Figure 1f-
1h). In dystrophic muscle, repeated rounds of degeneration 
and subsequent regeneration replace contractile muscle 
tissue with non-contractile fibrotic tissue, leading to a 
gradual loss of muscle strength in dystrophic muscle 
[30]. Consistent with improved muscle regeneration, 
Irisin injected mdx muscle had a pronounced reduction in 
fibrotic tissue accumulation (Figure 4b and 4c). Moreover, 
a significant, 43% reduction in necrotic muscle fibers 
(Figure 4d) was also observed after Irisin treatment, 
suggesting that injection of Irisin imparts protection 
against muscle degeneration and necrosis in adult mdx 
mice. It is important to mention that Irisin injection 
was able to reduce myofiber necrosis in adult mdx mice 
(~43%) (Figure 4d) to a greater extent than in young mdx 
mice (~9%) (Figure 2b), suggesting that Irisin effect may 
be more pronounced in adult mdx mice.
IgM is an antibody secreted by B cells and it 
is found mainly in circulation [31]. During muscular 
dystrophy, the sarcolemma of dystrophic muscle fibers 
become unstable and as such sarcolemmal integrity 
is compromised [32]. As a consequence of this, IgM, 
despite being a 900kDa molecule, is able to gain entry 
and accumulate in damaged myofibers [26]. A reduction 
of IgM accumulation in dystrophic muscle fibers is 
indicative of improvement of sarcolemmal stability [33]. 
Importantly, a distinct reduction in IgM accumulation was 
noted in myofibers of adult mdx mice injected with Irisin 
(Figure 4e and 4f), further validating the role of Irisin in 
maintaining sarcolemma integrity during dystrophy.
Utrophin is the autosomal paralogue of dystrophin 
and in fact has a similar function and structure to 
dystrophin [34]. Given this, Utrophin is able to compensate 
for the lack of dystrophin in dystrophic muscle and 
hence, the expression of Utrophin is typically higher in 
dystrophic conditions [35]. However, we did not observe 
a distinct difference in Utrophin levels in both young 
(Figure 2e and 2f) and adult mdx mice (Figure 4g and 
4h), after injection with Irisin, although we did notice an 
increase in muscle mass (Figure 1d and 1e, Figure 3c and 
3d), improved muscle strength (Figure 5e) and reduced 
fibrosis (Figure 4b and 4c). These data suggest that Irisin-
mediated improvement of the muscle phenotype in mdx 
mice may not be due to Irisin signalling via Utrophin.
As alluded to above, Irisin injection was able to 
confer a greater protective effect on skeletal muscle in 
adult mdx mice, when compared to the young mdx mice. 
Notably, a more distinct increase in myofiber hypertrophy 
(Figure 3e-3g) and reduction in myofiber necrosis (Figure 
4d) was observed in adult mdx mice after injection with 
Irisin. We propose that the difference in Irisin effect 
between young and adult mdx mice could be attributed 
to the natural stabilization of the dystrophic phenotype in 
adult mice [8, 24]. Hence, Irisin is able to exert a greater 
beneficial effect on muscle in adult mdx mice, which 
display low grade chronic pathology, as opposed to young 
mdx mice, which show more acute muscle damage [8, 24]. 
Importantly, prolonging the duration of Irisin injection 
in mdx mice resulted in a more pronounced increase in 
skeletal muscle mass and improvement of skeletal muscle 
function. These data underscore the pro-myogenic capacity 
of Irisin and further reveal that prolonged treatment with 
Irisin may impart greater improvement to mdx mice.
Previous work has revealed that loss of myostatin 
leads to increased expression of FNDC5 and Irisin [14]. 
Myostatin is a potent negative regulator of skeletal muscle 
mass and importantly, inhibition of Myostatin has been 
shown to reduce the severity of dystrophy, increase 
muscle strength [36] and reduce fibrosis in mdx mice [37]. 
Therefore we propose that Irisin may play a role in the 
enhanced muscle growth and reduced fibrosis noted in 
mdx mice in response to loss of myostatin. In agreement 
with this, we have shown that Irisin not only reduces 
fibrotic tissue accumulation (Figure 4b and 4c), but also 
improves muscle strength (Figure 5e) and skeletal muscle 
hypertrophy in mdx mice (Figures 1g and 1h, Figure 3f 
and 3g).
IGF-1 has been shown to rescue muscle loss in 
mdx mice and significantly reduce fibrosis [3]. Recent 
studies have revealed that treatment with Irisin results 
in upregulation of IGF-1 in human myocytes [15] and 
moreover, circulating Irisin levels have been positively 
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correlated with IGF-1 in humans [13]. Taken together, 
these data suggest that the improved musculature and 
reduced fibrosis noted in mdx mice in the present study 
may be due to elevated IGF-1 levels. However, further 
work will need to be performed to validate this hypothesis.
Since Irisin is an exercise induced myokine and 
is found in significantly higher concentrations post-
exercise [12], and given the pro-myogenic function 
of Irisin revealed in the current study, we propose 
that Irisin could be the molecule, which mediates the 
beneficial effects of exercise on skeletal muscle, without 
the associated muscle damage due to excessive physical 
exertion. This is particularly relevant in conditions such 
as DMD where exercise has been shown to exacerbate 
disease symptoms [38]. Overall, the results presented 
in this report show that Irisin may be a promising 
therapeutic target for the intervention of muscle 
dystrophy.
MATERIALS AND METHODS
Purification of recombinant irisin protein
cDNA corresponding to murine Irisin (amino 
acids 29-140 of FNDC5) was PCR amplified and 
cloned in frame into the pET-16b T7 expression vector, 
as per standard molecular biological techniques, and 
the resulting plasmid was transformed into the BL21 
strain of E.coli (Agilent Technologies, USA). The 
recombinant murine Irisin protein was induced and 
purified to homogeneity using Ni-Agarose resin under 
native conditions. Purified Irisin protein was dialyzed 
for three hours against buffer containing 50mM Tris-
HCl (pH 8.0), 500 mM NaCl and 10% Glycerol (dialysis 
buffer, DB) with three changes. Endotoxin in the purified 
Irisin protein was estimated using the ToxinSensor 
Chromogenic LAL kit, according to the protocol supplied 
with the kit.
Western blot analysis
In order to extract proteins, muscle tissue (thirty 
milligrams) homogenates were prepared in RIPA buffer 
(1x Phosphate buffered saline, 1% IGEPAL CA-630 
(v/v), 0.1% Sodium dodecyl sulfate (w/v), 0.5% Sodium 
deoxycholate (w/v)), 50mM Sodium fluoride) using the 
Tissue Lyser II disruptor (Qiagen, USA) at 30Hz (3 x 1 
minute). After centrifugation of homogenized muscle 
tissue for 10 minutes at 12,000 rpm, supernatant was used 
for protein estimation and western blot analysis. 50μg 
of total protein was separated by SDS-PAGE (8% Tris-
Glycine acrylamide gel) and transferred to nitrocellulose 
membrane by electroblotting. Membranes were stained 
with Ponceau S (Fluka, Sigma-Aldrich, USA) to confirm 
equal loading of protein samples. The membranes were 
blocked for 1 hour at room temperature with 5% milk 
(Sigma, USA) in TBST and subsequently incubated with 
either anti-Utrophin (1:200, Santa Cruz, SC-33700) or 
anti-Vinculin (1:5000, Sigma Aldrich, V9131) primary 
antibodies overnight at 4°C. The membranes were washed 
with TBST (3 x 10 minutes), followed by secondary 
antibody incubation for 1 hour at room temperature (RT). 
Secondary antibodies used in this paper were anti-mouse 
HRP (1:5000, Bio-Rad USA). Following secondary 
antibody incubations, membranes were washed as stated 
above and HRP activity was detected using Western 
Lighting Chemiluminescence Reagent Plus (NEL104; 
PerkinElmer Life Sciences, USA). Bands were detected 
using the ChemiDoc Touch Imaging System (BioRad, 
USA) and were analyzed using Image Lab software 
(BioRad, USA).
Animal care and treatment
Male mdx mice were bred in the Nanyang 
Technological University (NTU) animal house, 
Singapore. Animal experiments were performed 
according to the protocols approved by the NTU 
Institutional Animal Care & Use Committee (IACUC), 
Singapore. Mice were housed at a constant temperature 
of 20°C under an artificial 12h light and 12h dark cycle 
with ad libitum access to standard chow diet and water 
at NTU animal house. To monitor the effect of Irisin on 
dystrophic muscle growth, three trials were performed. 
In the first trial, 3-week-old mdx mice were injected 
with either recombinant Irisin protein (2.5μg of Irisin 
per gram of body weight) or DB for two weeks, three 
times-a-week and all hind limb muscles were collected 
for extensive characterization of the mdx phenotype 
and the role of Irisin in mdx mice. Cross sectional area 
(CSA) and extent of muscle fiber damage was analyzed. 
A second trial was performed in order to assess the CSA 
and fibrotic tissue accumulation by injecting 6-week- 
old mdx mice with either recombinant Irisin protein 
(2.5μg of Irisin per gram of body weight) or DB three 
times-a-week for a total of 2 weeks. In the final trial, 
4-week-old mdx mice were injected intraperitoneally 
(IP) with either recombinant Irisin protein (2.5μg of 
Irisin per gram of body weight) or DB three times-a-
week for a total of 4 weeks to analyze if a longer period 
of treatment enhances muscle weight and grip strength. 
Grip strength was measured just prior to the dissection 
in the final trial. Six readings were obtained for each 
mouse with a 30 seconds rest between each reading. 
The highest three values were used to calculate the 
average grip strength for each mouse in both the DB 
and Irisin injected groups. Measurements were recorded 
in Newtons (N). Food intake was measured before 
every injection. At the end of each trial, mice were 
euthanized by CO2 asphyxiation and various hind limb 
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muscles were harvested, weighed and stored for further 
experiments. The weights of the hind limb muscles were 
normalized to the tibia lengths of respective mice. TA 
muscle tissue was embedded in O.C.T (Sakura Finetek, 
USA), and stored at -80°C.
Muscle histology
For performing muscle histology, 10μm TA 
muscle transverse sections were generated from the 
midbelly region of O.C.T embedded muscle tissue 
using a Cryostat (Leica CM 1950, Germany). The 
muscle sections were stained with Gill’s Haematoxylin 
followed by 1% Eosin (Merck) (H&E). The cross 
sectional area of 200 muscle fibers from 5 random fields 
(1000 fibers) were analyzed per section. Myofibers 
that contained centrally placed nuclei were counted 
and normalized as a percentage of the total number of 
myofibers in the muscle section using ImageJ software 
(National Institutes of Health, USA). Necrotic muscle 
fibers were assessed based on the areas of fragmented 
sarcoplasm, influx of mononucleated cells and hyper-
contracted muscle fibers. Muscle sections were tiled 
using the Leica CTR 6500 microscope, equipped 
with the Leica DFC 420 camera and Image Pro Plus 
software (Media Cybernetics, Bethesda, MD) and a 10x 
objective. Representative images were taken at a higher 
magnification (20x objective).
Measurement of fibrosis
Muscle sections were stained using the Sirius 
Red/Fast Green collagen staining kit, as per the 
manufacturer’s protocol (Chondrex Inc, WA). Muscle 
sections were immersed in dye solution for 30 minutes 
at room temperature and excess dye was washed off 
with distilled water. Stained sections were then dried 
and mounted using DPX mounting medium (Merck, 
USA). The tissue sections were photographed and 
tiled using the Leica CTR 6500 microscope, equipped 
with the Leica DFC 420 camera and Image Pro Plus 
software (Media Cybernetics, Bethesda, MD) and a 10x 
objective. Representative images were taken at a higher 
magnification (40x objective). The extent of collagen 
deposition (red stain) was quantified by determining the 
total area that was stained red across the entire muscle 
cross section. The total area stained red was normalized 
to the total TA muscle section area and expressed as a 
percentage, to represent percentage fibrosis.
Immunohistochemical staining of muscle 
sections
To detect IgM accumulation in muscle fibers, 
muscle sections were fixed with ice-cold acetone for 2 
minutes and washed 3 times with 1xPBS for 5 minutes 
each. Blocking was performed for 1 hour at room 
temperature with 1% BSA and 5% horse serum in 1x 
PBS. Sections were subsequently incubated with Goat 
anti-mouse IgM-FITC conjugated antibody (1:100, 
Sigma Aldrich, F9259) for 1 hour and washed again 
3 times with 1xPBS for 5 minutes each. Sections 
were mounted with Slowfade Gold anti fade reagent 
(Molecular Probes) and visualized and tiled using 
the Leica CTR 6500 microscope, equipped with the 
Leica DFC 420 camera and Image Pro Plus software 
(Media Cybernetics, Bethesda, MD) and a 10x 
objective. Representative images were taken at a higher 
magnification (20x objective). Stained samples were 
analyzed and IgM positive fibers were counted, with 
the number of IgM positive myofibers expressed as a 
percentage of total muscle fiber area.
Injection of evans blue dye
5-week-old male mdx mice were injected 
intraperitoneally with a solution of 1% Evans Blue Dye 
(EBD) at a volume of 10μl per gram body weight 24h 
prior to hind limb muscle collection. The extent of EBD 
accumulation was assessed based on the area of the muscle 
section that displayed red fluorescence, expressed as a 
percentage of the total area of the muscle section. Sections 
were visualized and tiled using the Leica CTR 6500 
microscope equipped with the Leica DFC 420 camera and 
Image Pro Plus software (Media Cybernetics, Bethesda, 
MD) and a 10x objective. Representative images were 
taken at a higher magnification (20x objective).
Creatine kinase assay
Creatine kinase (CK) assay was performed to 
assess the extent of muscle damage in the mdx mice 
injected with either DB or Irisin. CK is usually present 
in skeletal muscle, but leaks into the serum upon muscle 
fiber damage. CK assay was performed using a Creatine 
Kinase Activity Assay Kit (KA3766), according to the 
manufacturer’s protocol. CK activity was measured in a 
clear bottom 96-well plate at 450 nm using a Microplate 
Spectrophotometer (BioRad, USA) and the MPM 6 
software. Calculations were performed according to the 
manufacturer’s instructions and creatine kinase values 
were represented as mU/mL.
Statistical analysis
Two-tailed Student’s t-test was used to compare 
differences between two groups. Equal variance between 
the two groups was determined by performing an F test 
on data prior to performing the Student’s t-test. If the 
F-value was smaller than F-critical (Type 2 error), the 
variance between the two groups was deemed equal. 
However, when the F-value was greater than F-critical 
values (Type 3 error) then the variance was deemed to be 
unequal. Results were considered significant at p< 0.05 
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(*), p< 0.01 (**) and p< 0.001(***). Data is presented as 
mean ± SEM.
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